Unknown

Dataset Information

PD-1 Monotherapy Reigns Supreme in Adjuvant Melanoma…But for How Long?


ABSTRACT: The results of CheckMate-238 led to the original FDA approval of anti-PD-1 therapy in high-risk, resectable melanoma. In this CCR Translations, we discuss the 5-year update of this pivotal trial and contextualize its results in the face of limited survival data, neoadjuvant therapy, next-generation biomarkers, and novel immunotherapy combinations. See related article by Larkin et al., p. 3352.

SUBMITTER: Augustin RC 

PROVIDER: S-EPMC10527539 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature